Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Congress 2023 Congress Watch

Don't miss our articles on selected Late-Breaking Abstracts!
Image-Guided Therapy;  Endocrine Therapy;  Prostate Cancer

LuPSMA Plus Enzalutamide Extends High-Risk Metastatic CRPC Survival

From ESMO Congress 2023:
Combining prostate-specific membrane antigen-targeted radiotherapy and enzalutamide improves progression-free survival versus enzalutamide alone for high-risk metastatic castration-resistant prostate cancer

Targeted Therapy;  Molecular Oncology;  Urothelial Cancer

THOR-2 Shows Erdafitinib RFS Gain For Progressive FGFR-Mutated NMIBC

From ESMO Congress 2023:
Patients with progressive non-muscle-invasive bladder cancer and select FGFR mutations have better recurrence-free survival with oral erdafitinib than an investigator’s choice of intravesical chemotherapy

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.